Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Biocytogen
company
About
Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.
- 1001 - 5000
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- ¥543M
- Industries
- Biotechnology,Health Care,Medical Device,Therapeutics
- Founded date
- Nov 1, 2008
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥1.51B
Biocytogen has raised a total of
¥1.51B
in funding over 2 rounds. Their latest funding was raised on
Sep 15, 2020 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 15, 2020 | Series D | ¥0.97B | 1 | — | — | Detail |
| Aug 8, 2019 | Series D | ¥543M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Biocytogen is funded by 1 investors.
China Life Healthcare Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
